DN-101 / DAAN Biotherap - LARVOL DELTA

‘TCR treatment’ Daan Biotherapeutics attracts KRW 23 billion Series A investment [Google translation] (HIT News) - "Daan Biotherapeutics...announced on the 25th that it has confirmed to attract 23 billion won in investment in the Series A investment round...This investment is aimed at supporting the company's growth and entry into the global market, including preclinical and clinical development of 'DN-101 (development code name)', a leading cell therapy pipeline...The goal is to treat EGFR mutant lung cancer....The goal is to conduct clinical trials of DN-101, a leading pipeline cell therapy product, in 2026."

Financing • New trial • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Solid Tumor • EGFR